Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 6Active not recruiting 3Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Glioblastoma 5Colorectal Neoplasms 5Breast Neoplasms 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Glioma 3Solid Tumors 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Multiple Myeloma 2Melanoma 2Carcinoma, Renal Cell 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Solid Tumor 1Primary Myelofibrosis 1Polycythemia Vera 1Papillomavirus Infections 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Neuroma, Acoustic 1Neuroma 1

Interventions

duvelisib 1Vincristine 1Prednisone 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Lymphoma, T-Cell × 30 days × Clear all
NCT04803201 2026-06-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
170 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡